合并代谢功能障碍相关脂肪性肝病对原发性胆汁性胆管炎结局产生不良影响
该研究基于两个中心的129例经组织学确诊的原发性胆汁性胆管炎(PBC)患者长期随访数据,其中36例组织学证实合并代谢功能障碍相关脂肪性肝病(MASLD)。合并MASLD的患者在巴黎II、多伦多、12个月AST-血小板比率、Globe及UK PBC评分上均显示更差预后,肝相关死亡和肝移植更常见,多因素分析显示脂肪变、血脂异常和晚期纤维化与不良结局独立相关。
要点
- 合并MASLD的PBC患者巴黎II应答率61.1% vs 33.3%,多伦多应答率52.5% vs 24.7%,均提示预后更差。
- 合并MASLD组Globe>0.30为49.2% vs 29.2%,UK PBC 5、10、15年评分均更差(p≤0.001)。
- 脂肪变、血脂异常和晚期纤维化与PBC不良结局独立相关。
核心结论
- 研究结果提示代谢功能障碍相关脂肪性肝病会加重原发性胆汁性胆管炎的预后。
研究设计与样本
- 来自两个中心的患者队列,包含长期随访数据,所有患者均经组织学确诊为原发性胆汁性胆管炎。
- 活检按非酒精性脂肪性肝炎临床研究网络标准分类,脂肪变超过5%且至少合并一项代谢危险因素时诊断为代谢功能障碍相关脂肪性肝病。
- 排除具有特定脂肪变病因、其他肝病、结果不完整及熊去氧胆酸治疗不充分的患者,开始二线治疗的患者数据被删失。
- 共纳入129例患者,其中36例组织学证实存在原发性胆汁性胆管炎与脂肪变的合并。
主要发现
- 合并脂肪变组巴黎II应答率61.1% vs 无合并组33.3%(p=0.004)。
- 合并脂肪变组多伦多应答率52.5% vs 无合并组24.7%(p=0.002)。
- 12个月AST-血小板比率>0.54者合并脂肪变组36.1% vs 无合并组17.2%(p=0.021)。
- Globe>0.30者合并脂肪变组49.2% vs 无合并组29.2%(p=0.033),UK PBC在5、10、15年评分差异均p≤0.001。
- 肝相关死亡和肝移植在合并脂肪变组更常见(p=0.001),多因素分析中脂肪变、血脂异常和晚期纤维化与更差结局独立相关。
关键数值与推荐
- 治疗应答采用12个月时的多伦多、巴黎II和AST-血小板比率标准评估。
- 结局指标采用UK PBC评分、Globe评分和肝脏事件。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: The relationship between primary biliary cholangitis (PBC) and metabolic dysfunction-associated steatotic liver disease, and its impact on treatment response and prognosis, remains underexplored. METHODS: Patient cohort from two centres comprising long-term follow-up data. All patients had histologically confirmed PBC. Biopsies were classified according to Non-Alcoholic Steatohepatitis Clinical Research Network. Diagnosis of metabolic dysfunction-associated steatotic liver disease was established when steatosis exceeded 5%, along with at least one metabolic risk factor. Patients with specific aetiologies of steatosis, other liver diseases, incomplete results and inadequate treatment with ursodeoxycholic acid were excluded. Data from patients initiating second-line treatment were censored. Treatment response was assessed using the Toronto, Paris II and AST-to-platelet at 12-month criteria. The UK PBC and Globe scores, and liver events were utilized as outcome measures. RESULTS: The study included 129 patients, 36 showing histologically confirmed overlap between PBC and steatosis. Patients with overlap showed worse prognosis according to Paris II (61.1% vs. 33.3%, p = 0.004), Toronto (52.5% vs. 24.7%, p = 0.002), AST-to-platelet 12-month >0.54 (36.1% vs. 17.2%, p = 0.021), Globe >0.30 (49.2% vs. 29.2%, p = 0.033) and UK PBC at 5, 10 and 15 years (p ≤ 0.001). Liver-related mortality and liver transplant were more prevalent in the overlap group (p = 0.001). In the multivariate analysis, steatosis, dyslipidaemia and advanced fibrosis were independently associated to worse outcomes. CONCLUSIONS: Our findings suggest that metabolic dysfunction-associated steatotic liver disease worsens the prognosis of PBC.
引用
- Hernández-Pérez M, Riado D, Pena E, et al. The overlap with metabolic dysfunction-associated steatotic liver disease negatively affects outcomes of primary biliary cholangitis. Aliment Pharmacol Ther. 2024. PMID: 38924185. doi:10.1111/apt.18134
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。